| Robert Bruce Thompson, MD | |
|
419 Earl Road, Shelby, NC 28150 | |
| (704) 481-0555 | |
| (704) 481-9169 |
| Full Name | Robert Bruce Thompson |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 419 Earl Road, Shelby, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780728428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 40006 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Bruce Thompson, MD Po Box 2489, Shelby, NC 28151 Ph: (704) 481-0555 | Robert Bruce Thompson, MD 419 Earl Road, Shelby, NC 28150 Ph: (704) 481-0555 |
News Archive
Britain's Health Secretary John Reid today announced that genetic test results used to predict possible future illness will not be used to deny people insurance.
Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).
An editorial challenges physicians and the U.S. healthcare system to reconsider the current "one size fits all" care for diverticulitis and to employ a precision medicine approach to determine which patients should be referred for colonoscopy.
Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
› Verified 2 days ago
Dr. John M Billinsky Jr., MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 201 E Grover St, Shelby, NC 28150 Phone: 980-487-3929 Fax: 980-487-3931 | |
Dr. Kerry Layne Balentine, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 418 S. Washington St., Shelby, NC 28150 Phone: 704-692-9380 Fax: 833-605-5203 | |
Hos Cyrus Loftus, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 202 E Grover St, Ste 1, Shelby, NC 28150 Phone: 980-487-2360 | |
Kevin M. Klein, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 202 E Grover St, Ste 1, Shelby, NC 28150 Phone: 980-487-2360 | |
Howard K Mason, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1201 S Post Rd Ste 100, Shelby, NC 28152 Phone: 704-481-7001 Fax: 704-445-4582 | |
Bernesta Charntel Williams, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 202 E Grover St, Ste 1, Shelby, NC 28150 Phone: 980-487-2360 |